Evaluation of antibody response to BNT162b2 mRNA COVID-19 vaccine in patients affected by immune-mediated inflammatory diseases up to 5 months after vaccination

SARS-CoV-2 vaccination with mRNA product BNT162b2 elicited high immunogenicity in healthy subjects in trials. This study aims to better understand the factors that influence the humoral immune response to vaccination against SARS-CoV-2 in patients with immune-mediated inflammatory diseases (IMIDs)....

Descripción completa

Detalles Bibliográficos
Autores principales: Firinu, Davide, Perra, Andrea, Campagna, Marcello, Littera, Roberto, Fenu, Giuseppe, Meloni, Federico, Cipri, Selene, Sedda, Francesca, Conti, Maria, Miglianti, Michela, Costanzo, Giulia, Secci, Marta, Usai, Gianmario, Carta, Mauro Giovanni, Cappai, Riccardo, Orrù, Germano, Del Giacco, Stefano, Coghe, Ferdinando, Chessa, Luchino
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8570239/
https://www.ncbi.nlm.nih.gov/pubmed/34741188
http://dx.doi.org/10.1007/s10238-021-00771-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8570239/
https://www.ncbi.nlm.nih.gov/pubmed/34741188
http://dx.doi.org/10.1007/s10238-021-00771-3

Ejemplares similares